Rising Cancer Incidence Drives Growth In The Aurora Kinase B Market: A Significant Driver Propelling The Aurora Kinase B Market In 2025

The Aurora Kinase B Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Aurora Kinase B Market Size and Projected Growth Rate?
In recent times, there has been a significant expansion in the aurora kinase b market. It is expected to rise from a value of $1.14 billion in 2024 to $1.27 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.1%. The notable growth during the historical period can be linked to factors such as a surge in demand for targeted cancer treatments, an uptick in the global incidence of cancer, a boost in investments in precision medicine, an increase in the volume of clinical trials, and enhanced government backing for cancer research.

In the upcoming years, the market size of aurora kinase b is predicted to experience swift expansion. It's anticipated to reach a size of $1.99 billion by 2029, with a compound annual growth rate (CAGR) of 11.8%. Factors contributing to this prospective growth include an increase in investment in innovative cancer treatments, the escalating occurrence of drug-resistant cancers, and a surge in research and development. Additionally, rising demand for combination therapies and increasing prevalence of solid tumors also fuel the growth. Significant trends that are expected to impact the market during the forecast period include technological advancements, precision medicine, innovative therapies, data analytics, as well as new therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20496

What Are the Major Segments in the Aurora Kinase B Market?
The aurora kinase b market covered in this report is segmented -

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Are The Driving Aurora Kinase B Market Evolution?
The escalating prevalence of cancer is projected to drive the expansion of the aurora kinase B market. This disease, which consists of an uncontrolled proliferation and dispersion of abnormal cells with potential to invade nearby tissues and spread throughout the body, is a primary concern. This increase in cancer cases can be attributed to factors like the aging population, changes in lifestyles, exposure to environmental hazards, and advancements in detection and diagnosis methods. Aurora kinase B is integral to the process of mitosis, and its overactivity is associated with chromosomal instability and cancer development. Owing to the role it plays in the division of tumor cells, it is frequently targeted in cancer treatments. For instance, the World Health Organization, based in Switzerland, reported in February 2024 that approximately 20 million new cancer cases were documented in 2022, resulting in around 9.7 million deaths. It is projected that by 2050, the number of new cancer cases will surge to over 35 million, marking a 77% growth from 2022. Hence, the increasing prevalence of cancer is spurring the growth of the aurora kinase B market.

Which Firms Dominate The Aurora Kinase B Market Segments?
Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

What Trends Are Expected to Dominate the Amnion Patch Market in the Next 5 Years?
Leading firms in the aurora kinase B market are taking innovative strides by developing products like aurora kinase inhibitors, which are strategically designed to interfere with vital cell division processes. Aurora kinase inhibitors are medicinal drugs that thwart the functions of Aurora kinases, essential components in cell division. This disruption of the cell division process inhibits the spread of cancer cells and possibly diminishes tumor size. To exemplify, Ellipses Pharma, a biotechnology firm based in the UK, declared in June 2023 that the U.S. Food and Drug Administration (FDA) had accepted its dual FLT-3 and Aurora kinase inhibitor, EP0042. This product is undergoing development as a remedy for acute myeloid leukemia (AML), serving as a dual target inhibitor for both FLT3 and Aurora kinase. This tactic is specifically customized for AML patients who have grown resistant to FLT3 inhibitors. Studies have shown that the combined inhibition of FLT3 and Aurora kinase can triumph over acquired resistance to selective FLT3 inhibition, in vitro and in vivo.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Is The Largest Region In The Aurora Kinase B Market?
North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Aurora Kinase B Market?
2. What is the CAGR expected in the Aurora Kinase B Market?
3. What Are the Key Innovations Transforming the Aurora Kinase B Industry?
4. Which Region Is Leading the Aurora Kinase B Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the aurora kinase b market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.